Human medicines European public assessment report (EPAR): Orserdu, elacestrant, Date of authorisation: 15/09/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 15, Status: Authorised

New clinical trial map launched in the EU

Regulatory Procedure Management (RPM) for the Product Lifecycle Management (PLM) - Frequently asked questions

Human medicines European public assessment report (EPAR): Spherox, spheroids of human autologous matrix-associated chondrocytes, Date of authorisation: 10/07/2017, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Date of authorisation: 15/09/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ruconest, conestat alfa, Date of authorisation: 28/10/2010, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Modigraf, tacrolimus, Date of authorisation: 15/05/2009, Revision: 21, Status: Authorised

Clinical Trials Information System (CTIS) bitesize talk: End of transition period and notifications including serious breach, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 October 2024, 15:30 (CEST) to 16 October 2024, 17:00 (CEST)

Clinical Trials Information System (CTIS) Bitesize Talk: Revised transparency rules and the new CTIS public portal, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 20 June 2024, 15:30 (CEST) to 20 June 2024, 17:00 (CEST)